87 related articles for article (PubMed ID: 12124955)
21. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?
Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D
Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241
[TBL] [Abstract][Full Text] [Related]
22. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
23. Tirofiban and emergency coronary surgery.
Shanmugam G
Eur J Cardiothorac Surg; 2005 Oct; 28(4):546-50. PubMed ID: 16126403
[TBL] [Abstract][Full Text] [Related]
24. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
[TBL] [Abstract][Full Text] [Related]
25. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
[TBL] [Abstract][Full Text] [Related]
26. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.
van 't Hof AW; Ernst N; de Boer MJ; de Winter R; Boersma E; Bunt T; Petronio S; Marcel Gosselink AT; Jap W; Hollak F; Hoorntje JC; Suryapranata H; Dambrink JH; Zijlstra F;
Eur Heart J; 2004 May; 25(10):837-46. PubMed ID: 15140531
[TBL] [Abstract][Full Text] [Related]
27. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.
White MM; Krishnan R; Kueter TJ; Jacoski MV; Jennings LK
J Thromb Thrombolysis; 2004 Dec; 18(3):163-9. PubMed ID: 15815877
[TBL] [Abstract][Full Text] [Related]
28. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
Huynh T; Piazza N; DiBattiste PM; Snapinn SM; Wan Y; Pharand C; Theroux P
Int J Cardiol; 2005 Apr; 100(1):73-8. PubMed ID: 15820288
[TBL] [Abstract][Full Text] [Related]
29. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
Rao AK; Sun L; Hiramatsu Y; Gorman JH; Edmunds LH
Thromb Haemost; 1999 Jul; 82(1):140-4. PubMed ID: 10456468
[TBL] [Abstract][Full Text] [Related]
30. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.
Puri A; Bansal A; Narain VS; Sethi R; Dwivedi SK; Puri VK; Saran RK
Indian Heart J; 2013; 65(2):152-7. PubMed ID: 23647894
[TBL] [Abstract][Full Text] [Related]
31. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention.
Danzi GB; Capuano C; Sesana M; Baglini R
Curr Med Res Opin; 2003; 19(1):28-33. PubMed ID: 12661777
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic modeling of the high-dose bolus regimen of tirofiban in patients with severe renal impairment.
Lakings DB; Janzen MC; Schneider DJ
Coron Artery Dis; 2012 May; 23(3):208-14. PubMed ID: 22441136
[TBL] [Abstract][Full Text] [Related]
33. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.
Schneider DJ; Herrmann HC; Lakkis N; Aguirre F; Wan Y; Aggarwal A; Kabbani SS; DiBattiste PM
Am J Cardiol; 2002 Dec; 90(12):1421-3. PubMed ID: 12480064
[No Abstract] [Full Text] [Related]
34. Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.
Hantgan RR; Stahle MC; Jerome WG; Nagaswami C; Weisel JW
Thromb Haemost; 2002 May; 87(5):910-7. PubMed ID: 12038797
[TBL] [Abstract][Full Text] [Related]
35. The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study.
Wong P; Harding S; Inglessis I; Choi CJ; Walters D; Chang Y; Gimelli G; Jang IK
J Thromb Thrombolysis; 2003 Dec; 16(3):163-6. PubMed ID: 15087602
[TBL] [Abstract][Full Text] [Related]
36. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).
Tcheng JE; Talley JD; O'Shea JC; Gilchrist IC; Kleiman NS; Grines CL; Davidson CJ; Lincoff AM; Califf RM; Jennings LK; Kitt MM; Lorenz TJ
Am J Cardiol; 2001 Nov; 88(10):1097-102. PubMed ID: 11703951
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].
Galli M; Vassanelli C
Ital Heart J Suppl; 2001 Oct; 2(10):1127-9. PubMed ID: 11723619
[No Abstract] [Full Text] [Related]
38. In vitro inhibition of platelet aggregation in response to increasing concentrations of tirofiban in patients with significant renal insufficiency.
Alam M; Gonzalez R; Delarosa A; Bobek J; Dokainish H; Lakkis N
Am Heart Hosp J; 2009; 7(1):17-20. PubMed ID: 19742428
[TBL] [Abstract][Full Text] [Related]
39. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).
Saucedo JF; Garza L; Wolford DC; Cook SL; Ramanathan KB; Matin Z; McGrew FA; Jacoski MV; Jennings LK;
Am J Cardiol; 2004 May; 93(10):1279-82. PubMed ID: 15135704
[TBL] [Abstract][Full Text] [Related]
40. Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention.
Azar RR; Badaoui G; Sarkis A; Kassab R; Salamé E; Aboujaoudé S; Hamdan R; Barakett V; Germanos M
Clin Cardiol; 2010 Jan; 33(1):E14-9. PubMed ID: 19816871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
